US EditionGenentech Biogen Owes $122M Royalties Trial Opens in California Federal Court - USA Herald
Summary by USA Herald
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Genentech Biogen Owes $122M Royalties Trial Opens in California Federal Court - USA Herald
The trial between Genentech Inc. and Biogen MA Inc. officially opened Monday in the U.S. District Court for the Northern District of California, centering on a $122 million royalties dispute related to Biogen’s multiple sclerosis drug, Tysabri. Genentech, a subsidiary of Roche Holding AG, alleges that Biogen owes $122 million in unpaid royalties for Tysabri
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
